Dealing with the remaining controversies of probiotic safety

M. Van Den Nieuwboer, E. Claassen

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

A clear safety profile of probiotics in clinical practice is essential in decision-making for all stakeholders and regulators. Probiotics have been investigated in different target populations, conditions and age groups. This also includes the use of probiotics in critically ill patients. Despite promising results reported with the use of probiotics and synbiotics, there is still a lively discussion regarding the proper and safe use of probiotics among physicians, researchers and regulators. This doubt and debate was sparked by the high incidence in mortality reported in a study with critically ill patients. Whereas no causal relationship has been established since, safety of probiotic has been questioned. In response, an overwhelming body of evidence suggesting that probiotics are safe has been compiled. Moreover, data indicates that probiotics reduce the number of adverse events compared to the control. However, due to a lack of standardised safety reporting in clinical studies, a strong evidence base on probiotic safety remains to be established. Here, we will discuss: (1) the rationale for using probiotics in the critically ill; (2) what happened during the Dutch Pancreatitis trial; (3) what are the known safety risks of probiotics based on the available data; and finally (4) how standardisation in safety reporting can drive probiotic innovation. Building a strong safety profile for probiotic strains will solidify its use in individuals that can benefit the most from microbial modulation.

Original languageEnglish
Pages (from-to)605-616
Number of pages12
JournalBeneficial Microbes
Volume10
Issue number6
Early online date27 May 2019
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Probiotics
Safety
Critical Illness
Synbiotics
Health Services Needs and Demand
Population Groups
Pancreatitis
Decision Making
Age Groups
Research Personnel

Keywords

  • Acute pancreatitis
  • Probiotics
  • PROPATRIA
  • Safety
  • Safety reporting

Cite this

Van Den Nieuwboer, M. ; Claassen, E. / Dealing with the remaining controversies of probiotic safety. In: Beneficial Microbes. 2019 ; Vol. 10, No. 6. pp. 605-616.
@article{701da22546284f749c5c48817760e47a,
title = "Dealing with the remaining controversies of probiotic safety",
abstract = "A clear safety profile of probiotics in clinical practice is essential in decision-making for all stakeholders and regulators. Probiotics have been investigated in different target populations, conditions and age groups. This also includes the use of probiotics in critically ill patients. Despite promising results reported with the use of probiotics and synbiotics, there is still a lively discussion regarding the proper and safe use of probiotics among physicians, researchers and regulators. This doubt and debate was sparked by the high incidence in mortality reported in a study with critically ill patients. Whereas no causal relationship has been established since, safety of probiotic has been questioned. In response, an overwhelming body of evidence suggesting that probiotics are safe has been compiled. Moreover, data indicates that probiotics reduce the number of adverse events compared to the control. However, due to a lack of standardised safety reporting in clinical studies, a strong evidence base on probiotic safety remains to be established. Here, we will discuss: (1) the rationale for using probiotics in the critically ill; (2) what happened during the Dutch Pancreatitis trial; (3) what are the known safety risks of probiotics based on the available data; and finally (4) how standardisation in safety reporting can drive probiotic innovation. Building a strong safety profile for probiotic strains will solidify its use in individuals that can benefit the most from microbial modulation.",
keywords = "Acute pancreatitis, Probiotics, PROPATRIA, Safety, Safety reporting",
author = "{Van Den Nieuwboer}, M. and E. Claassen",
year = "2019",
month = "6",
doi = "10.3920/BM2018.0159",
language = "English",
volume = "10",
pages = "605--616",
journal = "Beneficial Microbes",
issn = "1876-2883",
publisher = "Wageningen Academic Publishers",
number = "6",

}

Dealing with the remaining controversies of probiotic safety. / Van Den Nieuwboer, M.; Claassen, E.

In: Beneficial Microbes, Vol. 10, No. 6, 06.2019, p. 605-616.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Dealing with the remaining controversies of probiotic safety

AU - Van Den Nieuwboer, M.

AU - Claassen, E.

PY - 2019/6

Y1 - 2019/6

N2 - A clear safety profile of probiotics in clinical practice is essential in decision-making for all stakeholders and regulators. Probiotics have been investigated in different target populations, conditions and age groups. This also includes the use of probiotics in critically ill patients. Despite promising results reported with the use of probiotics and synbiotics, there is still a lively discussion regarding the proper and safe use of probiotics among physicians, researchers and regulators. This doubt and debate was sparked by the high incidence in mortality reported in a study with critically ill patients. Whereas no causal relationship has been established since, safety of probiotic has been questioned. In response, an overwhelming body of evidence suggesting that probiotics are safe has been compiled. Moreover, data indicates that probiotics reduce the number of adverse events compared to the control. However, due to a lack of standardised safety reporting in clinical studies, a strong evidence base on probiotic safety remains to be established. Here, we will discuss: (1) the rationale for using probiotics in the critically ill; (2) what happened during the Dutch Pancreatitis trial; (3) what are the known safety risks of probiotics based on the available data; and finally (4) how standardisation in safety reporting can drive probiotic innovation. Building a strong safety profile for probiotic strains will solidify its use in individuals that can benefit the most from microbial modulation.

AB - A clear safety profile of probiotics in clinical practice is essential in decision-making for all stakeholders and regulators. Probiotics have been investigated in different target populations, conditions and age groups. This also includes the use of probiotics in critically ill patients. Despite promising results reported with the use of probiotics and synbiotics, there is still a lively discussion regarding the proper and safe use of probiotics among physicians, researchers and regulators. This doubt and debate was sparked by the high incidence in mortality reported in a study with critically ill patients. Whereas no causal relationship has been established since, safety of probiotic has been questioned. In response, an overwhelming body of evidence suggesting that probiotics are safe has been compiled. Moreover, data indicates that probiotics reduce the number of adverse events compared to the control. However, due to a lack of standardised safety reporting in clinical studies, a strong evidence base on probiotic safety remains to be established. Here, we will discuss: (1) the rationale for using probiotics in the critically ill; (2) what happened during the Dutch Pancreatitis trial; (3) what are the known safety risks of probiotics based on the available data; and finally (4) how standardisation in safety reporting can drive probiotic innovation. Building a strong safety profile for probiotic strains will solidify its use in individuals that can benefit the most from microbial modulation.

KW - Acute pancreatitis

KW - Probiotics

KW - PROPATRIA

KW - Safety

KW - Safety reporting

UR - http://www.scopus.com/inward/record.url?scp=85069466252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069466252&partnerID=8YFLogxK

U2 - 10.3920/BM2018.0159

DO - 10.3920/BM2018.0159

M3 - Article

VL - 10

SP - 605

EP - 616

JO - Beneficial Microbes

JF - Beneficial Microbes

SN - 1876-2883

IS - 6

ER -